Jakarta, CNBC Indonesia – The Chinese pharmaceutical company Sinovac Biotech claims the Covid-19 vaccine being developed by the company produces antidote antibodies for elderly users.
This is the result of the company’s initial and intermediate trials. However, the immune response triggered by the vaccine in the elderly is lower than that of the young.
Sinovac spokesman Liu Peicheng said in the phase 1 and 2 clinical trials that took place in May 2020, there were 421 volunteers who were at least 60 years old. They were injected with CoronaVac and did not show any serious side effects, he said as quoted by Reuters, Tuesday (8/9/2020).
Unfortunately, until now the results of the Covid-19 vaccine research on the elderly have not been published by Sinovac in official health journals.
Currently, CoronaVac has entered its final stage of clinical trials, and is being tested in Brazil and Indonesia. This clinical trial will measure the effectiveness and safety of the vaccine to get approval for mass use.
China itself has given permission to use CoronaVac for emergencies. About 90% of employees and their families have been injected with the Covid-19 vaccine to protect people who are at high risk of infection.
Liu Peicheng added that this vaccine can last and is stable in storage for up to three years. This is one of the advantages of the Sinovac vaccine in distribution to remote and cold areas.
(roy/roy)
– .
